Marco Ruella

The paper identifies a multi-kingdom microbial consortium that normalizes immune responses in laboratory mice, altering cancer outcomes and CAR T cell therapy responses.

This study identifies SPTBN2 as a regulator of immunosuppressive tumor microenvironment and cross-resistance to therapies, showing its role in suppressing CAR T-cell efficacy.

This study identifies P2RX5-FL as a viable CAR T-cell target in diverse blood cancers, showing its expression in African ancestry individuals and its therapeutic potential in xenograft models.

This paper develops anti-CD2 CAR T-cells that overcome fratricide and improve efficacy by incorporating a PD-1:CD2 switch receptor to restore CD2 signaling.

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.